Tuesday, July 26, 2016

Sanofi Pasteur MSD’s new four-strain influenza vaccine now … – PharmiWeb.com (press release)

Sanofi Pasteur MSD’s brand-new four-strain influenza vaccine now approved in the UK

Sanofi Pasteur MSD UK
Posted on: 2six Jul 16

Maidenhead, UK – 2five July 201six – Sanofi Pasteur MSD UK announced today that the Medicines and Healthcare product and services Regulatory Agency (MHRA) has actually approved its Quadrivalent Influenza Vaccine (split virion, inactivated) cid:image004.png@01D1E663.EC3A4E90, which has 2 A strains (A/H1N1 and A/H3N2) and 2 B strains (B/Victoria and B/Yamagata) of the influenza virus. The vaccine is licensed for usage from 3six months of age. This is the newest addition to the longstanding Sanofi Pasteur MSD family of influenza vaccines.

The majority of seasonal influenza vaccines in the UK are currently trivalent,[i] meaning that they tips protect versus 3 strains of the influenza vaccine; 2 A strains and a solitary B strain. However, both distinct influenza B lineages (B/Victoria and B/Yamagata) now co-circulate global in varying and unpredictable proportions.[ii]  In the UK’s 2015-201six flu season, the influenza B/Yamagata-lineage (antigenically much like B/Phuket/3073/2013) was the component of the 2 trivalent and quadrivalent vaccines for the Northern Hemisphere. Yet of the 46two influenza B cases that were detected, 94 each cent (43two cases) belonged to the B/Victoria lineage (antigenically much like B/Brisbane/60/2008).[iii] This lineage was just included in quadrivalent formulations and not included in the trivalent vaccines advised by the globe Healthiness Organization.[iv] 

With co-move of both B strains, inclusion of the 2nd B strain in quadrivalent influenza vaccines can easily tips to give broader protection by minimising the impact of a mismatch of vaccine and disease-causing strains.[v] 

The globe Healthiness Organization involves quadrivalent influenza vaccines in its recommendations, stating

“Quadrivalent influenza vaccines that can potentially give wider protection versus influenza B viruses are becoming offered and tips need to not be restricted to trivalent vaccines.”2

If quadrivalent pretty compared to trivalent influenza vaccines were used in the UK over the past decade, it has actually been estimated that one more quarter of a million (227,790) influenza cases can have actually been avoided,5 including 5,940 influenza-related hospitalisations and 3,95five influenza-related deaths.5

“Quadrivalent influenza vaccines can easily tips permit UK healthcare professionals to offer wider protection versus the 2 often circulating B strains commented Dr Alex Dos Santos, Medical Director, Sanofi Pasteur MSD. “Prevention of influenza is a public Healthiness priority for the UK. We, at Sanofi Pasteur MSD are proud to keep on supporting vaccination Along with the progress of this brand-new vaccine, which will certainly be offered for usage for the 2017/18 flu season. “

Sanofi Pasteur MSD anticipates that quadrivalent vaccines will certainly come to be a brand-new standard in the prevention of influenza and is dedicated to functioning Along with healthcare professionals to tips protect eligible populations.
Editor’s Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 26/07/2016



from Influenza – NewsBlog http://ift.tt/29YtX1f